52 related articles for article (PubMed ID: 38581570)
21. TRIM proteins in hepatocellular carcinoma.
Lu K; Pan Y; Huang Z; Liang H; Ding ZY; Zhang B
J Biomed Sci; 2022 Sep; 29(1):69. PubMed ID: 36100865
[TBL] [Abstract][Full Text] [Related]
22. IκBζ regulates the development of nonalcoholic fatty liver disease through the attenuation of hepatic steatosis in mice.
Ishikawa H; Hayakawa M; Baatartsogt N; Kakizawa N; Ohto-Ozaki H; Maruyama T; Miura K; Suzuki K; Rikiyama T; Ohmori T
Sci Rep; 2022 Jul; 12(1):11634. PubMed ID: 35804007
[TBL] [Abstract][Full Text] [Related]
23. The nociceptin receptor promotes autophagy through NF-kB signaling and is transcriptionally regulated by E2F1 in HCC.
Zhou X; Chen D; Yan Y; Li Q; Xing W; Liu Y; Chen Y; Wang D; Yuan Y; Xie J; Zeng W; Pan J
Cell Death Discov; 2022 Apr; 8(1):165. PubMed ID: 35383175
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapies for hepatocellular carcinoma.
Liu JKH; Irvine AF; Jones RL; Samson A
Cancer Med; 2022 Feb; 11(3):571-591. PubMed ID: 34953051
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of NFKBIZ affects bladder cancer progression via the PTEN/PI3K/Akt signaling pathway.
Xu T; Rao T; Yu WM; Ning JZ; Yu X; Zhu SM; Yang K; Bai T; Cheng F
Int J Mol Med; 2021 Jun; 47(6):. PubMed ID: 33907827
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IκBζ target genes in hepatocytes.
He Y; Feng D; Hwang S; Mackowiak B; Wang X; Xiang X; Rodrigues RM; Fu Y; Ma J; Ren T; Ait-Ahmed Y; Xu M; Liangpunsakul S; Gao B
J Hepatol; 2021 Jul; 75(1):163-176. PubMed ID: 33610678
[TBL] [Abstract][Full Text] [Related]
27. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
28. EMT, cancer stem cells and autophagy; The three main axes of metastasis.
Babaei G; Aziz SG; Jaghi NZZ
Biomed Pharmacother; 2021 Jan; 133():110909. PubMed ID: 33227701
[TBL] [Abstract][Full Text] [Related]
29. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.
Tang W; Chen Z; Zhang W; Cheng Y; Zhang B; Wu F; Wang Q; Wang S; Rong D; Reiter FP; De Toni EN; Wang X
Signal Transduct Target Ther; 2020 Jun; 5(1):87. PubMed ID: 32532960
[TBL] [Abstract][Full Text] [Related]
30. TRIM E3 Ubiquitin Ligases in Rare Genetic Disorders.
Meroni G
Adv Exp Med Biol; 2020; 1233():311-325. PubMed ID: 32274764
[TBL] [Abstract][Full Text] [Related]
31. Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation.
Cardano M; Tribioli C; Prosperi E
Curr Cancer Drug Targets; 2020; 20(4):240-252. PubMed ID: 31951183
[TBL] [Abstract][Full Text] [Related]
32. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.
Xia S; Pan Y; Liang Y; Xu J; Cai X
EBioMedicine; 2020 Jan; 51():102610. PubMed ID: 31918403
[TBL] [Abstract][Full Text] [Related]
33. Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis.
Kakiuchi N; Yoshida K; Uchino M; Kihara T; Akaki K; Inoue Y; Kawada K; Nagayama S; Yokoyama A; Yamamoto S; Matsuura M; Horimatsu T; Hirano T; Goto N; Takeuchi Y; Ochi Y; Shiozawa Y; Kogure Y; Watatani Y; Fujii Y; Kim SK; Kon A; Kataoka K; Yoshizato T; Nakagawa MM; Yoda A; Nanya Y; Makishima H; Shiraishi Y; Chiba K; Tanaka H; Sanada M; Sugihara E; Sato TA; Maruyama T; Miyoshi H; Taketo MM; Oishi J; Inagaki R; Ueda Y; Okamoto S; Okajima H; Sakai Y; Sakurai T; Haga H; Hirota S; Ikeuchi H; Nakase H; Marusawa H; Chiba T; Takeuchi O; Miyano S; Seno H; Ogawa S
Nature; 2020 Jan; 577(7789):260-265. PubMed ID: 31853061
[TBL] [Abstract][Full Text] [Related]
34. Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy.
Yang J; Lin Y; Huang Y; Jin J; Zou S; Zhang X; Li H; Feng T; Chen J; Zuo Z; Zheng J; Li Y; Gao G; Wu C; Tan W; Lin D
Theranostics; 2019; 9(23):6856-6866. PubMed ID: 31660073
[TBL] [Abstract][Full Text] [Related]
35. Resveratrol Inhibits MMP3 and MMP9 Expression and Secretion by Suppressing TLR4/NF-
Zhang M; Xue Y; Chen H; Meng L; Chen B; Gong H; Zhao Y; Qi R
Oxid Med Cell Longev; 2019; 2019():9013169. PubMed ID: 31583048
[TBL] [Abstract][Full Text] [Related]
36. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies.
Alqahtani A; Khan Z; Alloghbi A; Said Ahmed TS; Ashraf M; Hammouda DM
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31450841
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib.
Abdelgalil AA; Alkahtani HM; Al-Jenoobi FI
Profiles Drug Subst Excip Relat Methodol; 2019; 44():239-266. PubMed ID: 31029219
[TBL] [Abstract][Full Text] [Related]
38. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach.
Lurje I; Czigany Z; Bednarsch J; Roderburg C; Isfort P; Neumann UP; Lurje G
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909504
[TBL] [Abstract][Full Text] [Related]
39. Exosomal FMR1-AS1 facilitates maintaining cancer stem-like cell dynamic equilibrium via TLR7/NFκB/c-Myc signaling in female esophageal carcinoma.
Li W; Zhang L; Guo B; Deng J; Wu S; Li F; Wang Y; Lu J; Zhou Y
Mol Cancer; 2019 Feb; 18(1):22. PubMed ID: 30736860
[TBL] [Abstract][Full Text] [Related]
40. Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCε-NF-κB signaling pathway and VEGF-C/ Bcl-2 expression.
Chen Y; Wang D; Peng H; Chen X; Han X; Yu J; Wang W; Liang L; Liu Z; Zheng Y; Hu J; Yang L; Li J; Zhou H; Cui X; Li F
Mol Cancer; 2019 Jan; 18(1):1. PubMed ID: 30609930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
